Fucaso (Equecabtagene Autoleucel) is an advanced, fully-human anti-BCMA CAR-T cell therapy approved for refractory/relapsed multiple myeloma. It utilizes a lentiviral vector to genetically modify autologous T cells. The CAR design incorporates a fully-human single-chain variable fragment (scFv), a CD8α hinge and transmembrane region, and domains for 4-1BB co-stimulation and CD3ζ activation.
Through meticulous molecular structure optimization and extensive functional assessments both in vitro and in vivo, Fucaso demonstrates rapid, robust efficacy along with exceptional long-term persistence in the body. This enables patients with multiple myeloma to achieve deeper and more durable remissions, offering sustained protection and care.
The FUMANBA-1 study, conducted across multiple sites in China, included 103 patients with relapsed or refractory multiple myeloma. Updated results were presented at ASCO 2023 (Abstract 8025), with a median follow-up of 13.8 months (range: 0.4–27.2 months).
| Brand | FUCASO | ABECMA | CARVYKTI | ZEVOR-CEL |
|---|---|---|---|---|
|
Approval |
ChinaJun. 2023 |
USAMar. 2021 |
USAFeb. 2022 |
ChinaFeb. 2024 |
|
Overall Response |
98.8% |
71% |
96.9% |
92.2% |
|
Complete Remission |
82.4% |
39% |
82.5% |
71.6% |
|
1Y PFS |
85.5% |
55% |
75% |
76.3 |
|
≥ L3 CRS |
1% |
9% |
5.1% |
6.9% |
|
≥ L3 ICANS |
0% |
4% |
5.2% |
0% |
Patient Assessment
Leukapheresis
Bridging Therapy
Lymphodepletation
CAR-T Infusion
Long-term Follow-up
China has experienced remarkable growth in the field of medicine over the past few decades, reflecting its broader advancements in science and technology. The country has made substantial investments in healthcare infrastructure, research, and development, which have significantly improved its medical capabilities. Cutting-edge facilities, increased funding for biomedical research, and a focus on innovation have enabled China to make strides in various areas of medicine, including CAR T-cell therapy.
CAR T-cell therapy has seen substantial progress in China, with several therapies approved for treating blood cancers like large B-cell lymphoma, acute lymphoblastic leukemia and multiple myeloma. The NMPA has streamlined approval processes, and domestic companies are actively developing new therapies and reducing costs. Research and clinical trials are vibrant, focusing on improving efficacy and managing side effects. China is making significant strides in expanding the availability and innovation of CAR T-cell therapies.
China has made significant strides in medical care and research, including advancements in CAR T-cell therapy.
China’s rapid advancements in biotechnologies are establishing it as a leader in CAR T-cell therapy, ensuring effective treatments.
China offers effective CAR T-cell therapies and other medical services with patient-friendly pricing and an accessible approach.
Timely treatment enhances recovery, reduces complications, and improves healthcare efficiency and patient satisfaction.
In China, Fucaso is only provided at certified treatment centers, these centers/hospitals usually are leading hospitals in the region, where the medical staff are highly skilled in managing multiple myeloma, and are specially trained to take care of you during the entire CAR T cell therapy process.
You should plan to stay at the certified treatment center for at least one week following the infusion, and you’ll have several appointments before and after the treatment. Your treatment team will advise you on how close you need to be to a certified healthcare facility during the first four weeks after the infusion.
